Inhibition of AKA in pancreatic cancer cells causes increased mitotic arrest and apoptosis, leading to decreased proliferation and tumorigenicity [9], with similar apoptotic synergy observed when added to EGFR inhibition in resistant pre-clinical models of EGFR-driven NSCLC [8]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.